PriceTargets.com logo

Oncology Institute - STLN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 24.18%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$6.85 As of 09/22/2026 12:12 PM ET
▲ +0.015 (0.22%)

This chart shows the closing price for STLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oncology Institute Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STLN

Analyst Price Target is $8.50
▲ +24.18% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Oncology Institute in the last 3 months. The average price target is $8.50, with a high forecast of $10.00 and a low forecast of $7.00. The average price target represents a 24.18% upside from the last price of $6.85.

This chart shows the closing price for STLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Oncology Institute. This rating has held steady since August 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/26/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/26/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/24/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/23/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/22/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/6/2026Weiss RatingsInitiated CoverageSell (D-)
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/9/2026BTIG ResearchBoost TargetBuy ➝ Buy$8.00 ➝ $9.00
7/6/2026Lake Street CapitalInitiated CoverageBuy$10.00
6/17/2026Needham & Company LLCBoost TargetBuy ➝ Buy$5.00 ➝ $7.00
6/8/2026BTIG ResearchBoost TargetBuy ➝ Buy$7.00 ➝ $8.00
4/20/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/13/2026B. Riley FinancialBoost TargetBuy ➝ Buy$6.00 ➝ $8.00
3/9/2026BTIG ResearchReiterated RatingBuy ➝ Buy$7.00
3/9/2026Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/25/2025Needham & Company LLCInitiated CoverageBuy$5.00
10/21/2025BTIG ResearchReiterated RatingBuy ➝ Buy$7.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/23/2025Noble FinancialInitiated CoverageOutperform$8.00
7/16/2025B. Riley FinancialInitiated CoverageBuy$6.00
7/15/2025B. Riley FinancialUpgradeStrong-Buy
5/15/2025BTIG ResearchInitiated CoverageBuy$7.00
2/26/2024Jefferies Financial GroupInitiated CoverageBuy$2.50
6/16/2023GuggenheimLower Target$3.00 ➝ $2.00
3/20/2023GuggenheimLower Target$6.00 ➝ $3.00
11/11/2022GuggenheimLower TargetBuy$7.00 ➝ $6.00
9/14/2022GuggenheimInitiated CoverageBuy$7.00
8/15/2022Jefferies Financial GroupInitiated CoverageBuy$10.00
(Data available from 9/22/2021 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2026
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2026
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2026
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2026
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2026
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2026
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2026

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Oncology Institute logo
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants for cancer patients. The company was founded in 2007 and is based in Cerritos, California.
Read More

Today's Range

Now: $6.85
Low: $6.77
High: $6.92

50 Day Range

MA: N/A

52 Week Range

Now: $6.85
Low: $2.32
High: $7.13

Volume

146,626 shs

Average Volume

1,820,665 shs

Market Capitalization

$676.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Oncology Institute?

The following Wall Street sell-side analysts have issued reports on Oncology Institute in the last twelve months: B. Riley Financial, Inc., BTIG Research, Lake Street Capital, Needham & Company LLC, and Weiss Ratings.
View the latest analyst ratings for STLN.

What is the current price target for Oncology Institute?

0 Wall Street analysts have set twelve-month price targets for Oncology Institute in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 24.5%. Lake Street Capital has the highest price target set, predicting STLN will reach $10.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $7.00 for Oncology Institute in the next year.
View the latest price targets for STLN.

What is the current consensus analyst rating for Oncology Institute?

Oncology Institute currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for STLN.

How do I contact Oncology Institute's investor relations team?

Oncology Institute's physical mailing address is 18000 STUDEBAKER RD, SUITE 800, CERRITOS, CA, 90703. The company's listed phone number is (562) 735-3226 and its investor relations email address is [email protected]. The official website for Oncology Institute is www.starlingoncology.com. Learn More about contacing Oncology Institute investor relations.